These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 8263548)
1. Modulatory effects of testosterone on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Dluzen D; Jain R; Liu B J Neurochem; 1994 Jan; 62(1):94-101. PubMed ID: 8263548 [TBL] [Abstract][Full Text] [Related]
2. Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease. Goshima Y; Misu Y; Arai N; Misugi K Jpn J Pharmacol; 1991 Jan; 55(1):93-100. PubMed ID: 1645816 [TBL] [Abstract][Full Text] [Related]
3. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice. Dluzen DE Brain Res; 1996 Apr; 715(1-2):113-8. PubMed ID: 8739629 [TBL] [Abstract][Full Text] [Related]
4. Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. Dluzen DE; McDermott JL; Liu B J Neurochem; 1996 Feb; 66(2):658-66. PubMed ID: 8592137 [TBL] [Abstract][Full Text] [Related]
5. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Rioux L; Frohna PA; Joyce JN; Schneider JS Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972 [TBL] [Abstract][Full Text] [Related]
6. Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice. Mizukawa K; Ogawa N; Sora YH Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):121-8. PubMed ID: 3258432 [TBL] [Abstract][Full Text] [Related]
7. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Sonsalla PK; Heikkila RE Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):345-54. PubMed ID: 3260386 [TBL] [Abstract][Full Text] [Related]
8. Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA. Melamed E; Rosenthal J; Globus M; Cohen O; Uzzan A Brain Res; 1985 Sep; 342(2):401-4. PubMed ID: 3876139 [TBL] [Abstract][Full Text] [Related]
10. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Muthane U; Ramsay KA; Jiang H; Jackson-Lewis V; Donaldson D; Fernando S; Ferreira M; Przedborski S Exp Neurol; 1994 Apr; 126(2):195-204. PubMed ID: 7925820 [TBL] [Abstract][Full Text] [Related]
11. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction]. Nishi K; Kondo T; Narabayashi H No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916 [TBL] [Abstract][Full Text] [Related]
12. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease. King JM; Muthian G; Mackey V; Smith M; Charlton C Life Sci; 2011 Oct; 89(17-18):638-43. PubMed ID: 21871902 [TBL] [Abstract][Full Text] [Related]
13. Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1). Marcotte ER; Chugh A; Mishra RK; Johnson RL Peptides; 1998; 19(2):403-6. PubMed ID: 9493876 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Arai N; Misugi K; Goshima Y; Misu Y Brain Res; 1990 May; 515(1-2):57-63. PubMed ID: 2357577 [TBL] [Abstract][Full Text] [Related]
15. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions. Sirinathsinghji DJ; Heavens RP; McBride CS Brain Res; 1988 Mar; 443(1-2):101-16. PubMed ID: 3258784 [TBL] [Abstract][Full Text] [Related]
16. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. Naskar A; Manivasagam T; Chakraborty J; Singh R; Thomas B; Dhanasekaran M; Mohanakumar KP J Pineal Res; 2013 Oct; 55(3):304-12. PubMed ID: 23952687 [TBL] [Abstract][Full Text] [Related]
17. The use of the MPTP-treated mouse as an animal model of parkinsonism. Heikkila RE; Sonsalla PK Can J Neurol Sci; 1987 Aug; 14(3 Suppl):436-40. PubMed ID: 3499967 [TBL] [Abstract][Full Text] [Related]
18. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Holmer HK; Keyghobadi M; Moore C; Meshul CK Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485 [TBL] [Abstract][Full Text] [Related]
19. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Jenner P; Marsden CD J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760 [TBL] [Abstract][Full Text] [Related]
20. Depletion of striatal dopamine by the N-oxide of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Lau YS; Fung YK; Trobough KL; Cashman JR; Wilson JA Neurotoxicology; 1991; 12(2):189-99. PubMed ID: 1956580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]